Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells

K. Kolostova, E. Pospisilova, R. Matkowski, J. Szelachowska, V. Bobek

. 2022 ; 71 (12) : 2901-2911. [pub] 20220426

Language English Country Germany

Document type Journal Article

E-resources Online Full text

NLK PubMed Central from 1982
ProQuest Central from 1997-03-01 to 1 year ago
Medline Complete (EBSCOhost) from 2000-04-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-03-01 to 1 year ago
Public Health Database (ProQuest) from 1997-03-01 to 1 year ago

BACKGROUND: Dendritic cell (DC) therapy counts to the promising strategies how to weaken and eradicate cancer disease. We aimed to develop a good manufacturing practice (GMP) protocol for monocyte-derived DC (Mo-DC) maturation using circulating tumor cells lysates with subsequent experimental T-cell priming in vitro. METHODS: DC differentiation was induced from a population of immunomagnetically enriched CD14 + monocytes out of the leukapheresis samples (n = 6). The separation was provided automatically, in a closed bag system, using CliniMACS Prodigy® separation protocols (Miltenyi Biotec). For differentiation and maturation of CD14 + cells, DendriMACs® growing medium with supplements (GM-CSF, IL-4, IL-6, IL-1B, TNFa, PGE) was used. Immature Mo-DCs were loaded with autologous circulating tumor cell (CTCs) lysates. Autologous CTCs were sorted out by size-based filtration (MetaCell®) of the leukapheresis CD14-negative fraction. A mixture of mature Mo-DCs and autologous non-target blood cells (NTBCs) was co-cultured and the activation effect of mature Mo-DCs on T-cell activation was monitored by means of multimarker gene expression profiling. RESULTS: New protocols for mMo-DC production using automatization and CTC lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation. Gene expression analysis revealed elevation for following genes in NTBC (T cells) subset primed by mMo-DCs: CD8A, CD4, MKI67, MIF, TNFA, CD86, and CD80 (p ≤ 0.01). CONCLUSION: Summarizing the presented data, we might conclude mMo-DCs were generated using CliniMACS Prodigy® machine and CTC lysates in a homogenous manner showing a potential to generate NTBC activation in co-cultures. Identification of the activation signals in T-cell population by simple multimarker-qPCRs could fasten the process of effective mMo-DC production.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032517
003      
CZ-PrNML
005      
20230131150812.0
007      
ta
008      
230120s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00262-022-03189-2 $2 doi
035    __
$a (PubMed)35471603
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kolostova, Katarina $u Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic
245    10
$a Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells / $c K. Kolostova, E. Pospisilova, R. Matkowski, J. Szelachowska, V. Bobek
520    9_
$a BACKGROUND: Dendritic cell (DC) therapy counts to the promising strategies how to weaken and eradicate cancer disease. We aimed to develop a good manufacturing practice (GMP) protocol for monocyte-derived DC (Mo-DC) maturation using circulating tumor cells lysates with subsequent experimental T-cell priming in vitro. METHODS: DC differentiation was induced from a population of immunomagnetically enriched CD14 + monocytes out of the leukapheresis samples (n = 6). The separation was provided automatically, in a closed bag system, using CliniMACS Prodigy® separation protocols (Miltenyi Biotec). For differentiation and maturation of CD14 + cells, DendriMACs® growing medium with supplements (GM-CSF, IL-4, IL-6, IL-1B, TNFa, PGE) was used. Immature Mo-DCs were loaded with autologous circulating tumor cell (CTCs) lysates. Autologous CTCs were sorted out by size-based filtration (MetaCell®) of the leukapheresis CD14-negative fraction. A mixture of mature Mo-DCs and autologous non-target blood cells (NTBCs) was co-cultured and the activation effect of mature Mo-DCs on T-cell activation was monitored by means of multimarker gene expression profiling. RESULTS: New protocols for mMo-DC production using automatization and CTC lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation. Gene expression analysis revealed elevation for following genes in NTBC (T cells) subset primed by mMo-DCs: CD8A, CD4, MKI67, MIF, TNFA, CD86, and CD80 (p ≤ 0.01). CONCLUSION: Summarizing the presented data, we might conclude mMo-DCs were generated using CliniMACS Prodigy® machine and CTC lysates in a homogenous manner showing a potential to generate NTBC activation in co-cultures. Identification of the activation signals in T-cell population by simple multimarker-qPCRs could fasten the process of effective mMo-DC production.
650    _2
$a lidé $7 D006801
650    12
$a dendritické buňky $x metabolismus $7 D003713
650    _2
$a faktor stimulující granulocyto-makrofágové kolonie $x farmakologie $7 D016178
650    _2
$a interleukin-4 $x farmakologie $7 D015847
650    _2
$a interleukin-6 $x farmakologie $7 D015850
650    12
$a monocyty $x metabolismus $7 D009000
650    12
$a nádorové cirkulující buňky $x metabolismus $7 D009360
650    _2
$a prostaglandiny E $x farmakologie $7 D011458
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pospisilova, Eliska $u Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic
700    1_
$a Matkowski, Rafal $u Department of Oncology, Wrocław Medical University, Wrocław, Poland $u Breast Cancer Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, Plac Hirszfelda 12, 54-413, Wrocław, Poland
700    1_
$a Szelachowska, Jolanta $u Department of Oncology, Wrocław Medical University, Wrocław, Poland $u Breast Cancer Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, Plac Hirszfelda 12, 54-413, Wrocław, Poland
700    1_
$a Bobek, Vladimir $u Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic. vbobek@centrum.cz $u 3rd Department of Surgery University Hospital Motol and 1st Faculty of Medicine, Charles University, V Uvalu 84, 15006, Prague, Czech Republic. vbobek@centrum.cz $u Department of Thoracic Surgery, Masaryk's Hospital, Krajska Zdravotni a.s., Socialni pece 3316/12A, 40113, Usti nad Labem, Czech Republic. vbobek@centrum.cz $u Department of Thoracic Surgery, Lower Silesian Oncology, Pulmology and Hematology Center and Medical University Wroclaw, Grabiszynska 105, 53-413, Wrocław, Poland. vbobek@centrum.cz $1 https://orcid.org/0000000289743577
773    0_
$w MED00001041 $t Cancer immunology, immunotherapy : CII $x 1432-0851 $g Roč. 71, č. 12 (2022), s. 2901-2911
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35471603 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131150808 $b ABA008
999    __
$a ok $b bmc $g 1891339 $s 1183852
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 71 $c 12 $d 2901-2911 $e 20220426 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...